表紙
市場調查報告書

過去十年中的傳染病大流行

Pandemic Outbreaks in the Past Decade: A BCC Research Overview

出版商 BCC Research 商品編碼 940537
出版日期 內容資訊 英文 76 Pages
訂單完成後即時交付
價格
過去十年中的傳染病大流行 Pandemic Outbreaks in the Past Decade: A BCC Research Overview
出版日期: 2020年06月02日內容資訊: 英文 76 Pages
簡介

本報告調查了過去10年中全球傳染病的流行情況,以及過去主要傳染病的流行情況以及病原微生物,爆發因素,流行病學,病理生理學,診斷/評估方法,治療它總結了管理法律,國家和國際努力以及從過去的大流行中汲取的經驗教訓。

第1章簡介

第2章:全球傳染病大流行:簡介

  • 致病微生物和傳染病:1973-2019年
  • 導致傳染病爆發的因素
  • 病毒爆發,流行和大流行的分類
  • 當前的時尚和潛力□全球時尚的潛力
  • 當前的大流行和潛力
  • 當前的應對技術
  • 恐怖主義生物武器
  • 下一個全球流行病
  • 人畜共患病毒的類型
  • 傳染病全球流行:歷史
  • 傳染病治療

第3章H1N1流感(豬流感)

  • 病因
  • 流行病學
  • 病理生理學
  • 流感病毒的類型
    • 甲型流感病毒
    • 乙型流感病毒
    • C型流感病毒
  • 診斷與評估
  • 治療/管理
  • 世界衛生組織和收容措施
  • 流感疫苗庫存
  • 流行前疫苗接種
  • 抗病毒性
  • 再生病毒
  • 無形的市場風險
  • 媒體報導和疫苗接種
  • 主要國家的國家計劃

第4章埃博拉病毒病

  • 病因
  • 流行病學
  • 臨床症狀
  • 診斷
  • 治療/管理

第5章MERS(中東呼吸綜合徵)

  • 病因
  • 流行病學
  • 病理生理學
  • 臨床特徵
  • 診斷
  • 治療/管理
  • 預防
  • 優先級:MERS的研究,監控,管理和控制

第6章新的冠狀病毒感染(SARS-CoV-2)

  • COVID-19症狀
  • COVID-19的進展
  • 潛伏期
  • 流行病學
  • 研發
  • 診斷/醫療技術
  • 需要重新設計呼吸機
  • COVID-19臨床試驗

第7章過去的經驗教訓

  • 維持基本醫療服務
  • 獲得預防/安全措施/測試/治療的途徑
  • 隔離與分離
  • 國際努力加強全球爆發對策系統

第8章附錄

目錄
Product Code: PHM232A

Highlights:

This report focuses on epidemiology, research and development, current treatment and diagnostics and global response to selected pandemics of the past decade (2009-2020). The report discusses lessons learned from previous outbreaks in terms of policies and measures of prevention and control.

Report Includes:

  • An overview of the pandemic outbreaks occurred over the last decade (2010-2020)
  • Discussion of several serious epidemiological outbreaks, their socioeconomic impact, R&D efforts, treatment and diagnostics, clinical trial landscape, and regulatory and reimbursement landscape
  • Data corresponding to number of confirmed cases and reported deaths (globally and country wise) due to various pandemics, including novel coronavirus disease (COVID-19), SARS, MERS, HIV/AIDS, H1N1, Ebola virus etc.
  • Correlation of coronavirus (Covid-19) outbreak to previous epidemiological outbreaks in terms of policies and measures of prevention and control, and the lessons learned thereafter
  • Insight into key scientific breakthroughs and pipeline products targeting infectious disease treatments, including the novel coronavirus disease and its antibody-based clinical program (antibody to MERS-CoV infection)

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2: Introduction to Pandemics

  • Pathogenic Microbes and Infectious Diseases: 1973-2019
  • Factors Contributing to the Emergence of Infectious Diseases
    • Human Demographics and Behavior
    • Technology
    • The Role of Needles
    • Economic Development and Land Use
    • International Travel
    • Microbial Adaptation
    • Antibiotic Development
  • Classifying Viral Outbreaks, Epidemics and Pandemics
  • Current and Potential Epidemics with Pandemic Potential
  • Current and Potential Pandemics
  • Current Technologies for Addressing Potential Pandemic Threats
  • Biological Weapons for Terrorism
  • The Next Pandemic
  • Types of Zoonotic Viruses
  • A Brief History of Global Pandemics
    • Bubonic Plague (1300 to the Present)
    • Cholera (1916-1966)
    • The Spanish Influenza Pandemic (1918)
    • Asian Flu Pandemic (1957-1958)
    • HIV/AIDS Pandemic (1980 to the Present)
    • Influenza A-H1N1 (2009 to the Present)
    • Malaria (2700 BC to the Present)
    • Severe Acute Respiratory Syndrome (SARS) (2002-2003)
    • Tuberculosis (4000 BC to the Present)
  • Treatments for Infectious Diseases
    • Prevention
    • Vaccination
    • Pharmaceutical Treatments

Chapter 3: H1N1 Influenza (Swine Influenza)

  • Etiology
  • Epidemiology
  • Pathophysiology
  • Types of Influenza Viruses
    • Influenza Virus A
    • Influenza Virus B
    • Influenza Virus C
  • Diagnosis and Evaluation
    • Real-Time Polymerase Chain Reaction
    • Nucleotide Sequencing
    • Phylogenetic Analysis
  • Treatment and Management
    • Prevention of Swine to Human Viral Transmission
    • Prevention of Human-to-Human Transmission
    • Vaccines
    • Antiviral Treatments
  • The WHO and Containment for Pandemic Influenza
  • International Influenza Vaccine Stockpile Orders
  • Pre-pandemic Vaccination
    • Biomedical Advanced Research and Development Authority (BARDA)
  • Antiviral Resistance
  • Recreated Viruses
  • Immaterialized Market Risk
  • Media Coverage and Vaccinations
  • Pandemic Preparedness Plans
    • United States
    • Japan
    • China
    • Brazil
    • United Kingdom

Chapter 4: Ebola Virus Disease

  • Etiology
  • Epidemiology
  • Clinical Manifestations
  • Diagnosis
  • Treatment/Management
    • Supportive Care
    • Therapeutics
    • Vaccines and Prevention

Chapter 5: Middle East Respiratory Syndrome

  • Etiology
  • Epidemiology
    • Geographical Distribution
    • Sources of Infection
    • Risk Factors and Transmission
  • Pathophysiology
  • Clinical Features
  • Diagnosis
    • Molecular Diagnostics
    • Serological Assays
  • Treatment and Management
    • Antiviral Agents
    • Convalescent Plasma
    • Antibiotic Therapy
    • Intensive Care Management
    • New Treatments
  • Prevention
    • Advances in Vaccine Development
  • Priorities: MERS Research, Surveillance, Management, and Control
    • Establishing a One Health Global Consortium
    • Priority Studies at the Animal-Human-Environmental Interface
    • Priority Studies in Human Populations
    • Priority Studies for Vaccines, Therapeutics, and Rapid Diagnostics

Chapter 6: Coronavirus Disease 2019 (SARS-CoV-2)

  • Symptoms of COVID-19
  • COVID-19 Progression
  • Incubation Period
  • Epidemiology
    • Case Fatality Rate (CFR)
    • Global Confirmed Cases and Confirmed Deaths Due to COVID-19
  • COVID-19 Research and Development
  • Diagnostics and Medtech
  • The Need to Reinvent Ventilators
  • Clinical Trials on COVID-19

Chapter 7: Lessons Learned from History

  • Maintaining Essential Healthcare Services
  • Access to Prevention, Safety Measures, Testing and Treatment
  • Quarantine and Isolation
  • International Efforts to Strengthen the Global Outbreak Response System
    • Africa Centers for Disease Control and Prevention
    • Coalition for Epidemic Preparedness Innovations
    • European Medical Corps
    • Regional Disease Surveillance Systems Enhancement Program
    • The WHO Global Health Emergency Workforce
    • The WHO R&D Blueprint
    • World Bank Pandemic Emergency Financing Facility

Chapter 8: Appendix

  • Acronyms

List of Tables

  • Table 1: Pathogenic Bacteria, Parasites and Viruses, 1973-2019
  • Table 2: History of Antibiotic Discovery and Approval, 1935-2013
  • Table 3: CDC: Six Phases of Classification of Viral Pandemics
  • Table 4: Technologies for Addressing Potential Pandemic Threats
  • Table 5: Diseases That Have Been or Can Be Weaponized
  • Table 6: Commercial Products of H1N1 Influenzas Diagnostics
  • Table 7: Neuraminidase Inhibitor Resistance Testing Results on Samples Collected Since October 1, 2017
  • Table 8: Essential and Desirable Elements of the WHO Influenza Pandemic Preparedness Plan
  • Table 9: Japan's Action Plan for Influenza Pandemic Preparedness
  • Table 10: China's Influenza Pandemic Warning Levels
  • Table 11: Brazil's Influenza Pandemic Warning Levels and Action
  • Table 12: Ebola Outbreaks Between 1976 and 2014
  • Table 13: Clinical Features of Ebola Virus Disease, by Stage
  • Table 14: Overview of Investigational Therapeutics Evaluated in Clinical Trials on Ebola Virus Disease During the 2013-2016 West African Outbreak
  • Table 15: Key Vaccines with Accelerated Clinical Development During the 2013-2016 Ebola Virus Disease Outbreak
  • Table 16: Molecular Diagnostic Tests for MERS-CoV Diagnosis, Single Assays
  • Table 17: Molecular Diagnostic Tests for MERS-CoV Diagnosis, Multiplex Assays
  • Table 18: Serology Tests for MERS-CoV Diagnosis
  • Table 19: Potential Therapies for MERS-CoV Infection
  • Table 20: Vaccines in the Pipeline for the Prevention of MERS-CoV Infection
  • Table 21: COVID-19 Symptoms by Percentage of Patients
  • Table 22: Case Fatality Rate of COVID-19, by Region, March 2020
  • Table 23: Case Fatality Rate of COVID-19, by Selected Country
  • Table 24: COVID-19: Confirmed Cases and Deaths, by Country, May 14, 2020
  • Table 25: COVID-19 Therapeutic Interventions in Development, by Biopharmaceutical Companies in Collaboration
  • Table 26: COVID-19 Therapeutics in Development, by Biopharmaceutical Company
  • Table 27: COVID-19 Vaccines in Development, by Biopharmaceutical Companies in Collaboration
  • Table 28: COVID-19 Vaccines in Development, by Biopharmaceutical Company
  • Table 29: Modifiable Breathing Devices Eligible for EUAs, by Company
  • Table 30: Number of Clinical Trials on COVID-19, by Phase
  • Table 31: Number of Clinical Trials on COVID-19, by Intervention
  • Table 32: Clinical Trials on COVID-19, by Country
  • Table 33: High-Level Initiatives Established Since the Ebola Crisis
  • Table 34: List of Acronyms

List of Figures

  • Figure 1: Number of Approved WHO Influenza Centers, by WHO Dedignated Region
  • Figure 2: Targeted Pre-pandemic Influenza Vaccine Stockpiles Based on Population Demand for Selected Countries
  • Figure 3: Geographical Distribution of Reported Human Infections of MERS-CoV
  • Figure 4: Infographic Comparison of CFR and Cases of the Three Major Beta Coronaviruses: MERS, SARS, and COVID-19
  • Figure 5: Distribution of Clinical Trials on COVID-19, by Phase
  • Figure 6: Distribution of Clinical Trials on COVID-19, by Intervention
  • Figure 7: Distribution of Clinical Trials on COVID-19, by Country
  • Figure 8: The Role of High-Level Initiatives in Enhancing the Three Main Phases of Global Outbreak Preparedness